H. Döhner

2.7k citations

27 papers · 1.8k indexed · 1 hit paper · h-index 19

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Genetics 18
- Chronic Lymphocytic Leukemia Research 17
- Genomic variations and chromosomal abnormalities 4
Pathology and Forensic Medicine 14
- Lymphoma Diagnosis and Treatment 14

Co-authors: Stephan Stilgenbauer (12 shared papers)Peter Lichter (8 shared papers)Martin Bentz (6 shared papers)Axel Benner (4 shared papers)Konstanze Fischer (3 shared papers)Richard F. Schlenk (2 shared papers)W. Hunstein (2 shared papers)Johannes Coy (1 shared paper)
Journals: Leukemia (8 papers)Haematologica (4 papers)Blood (3 papers)JNCI Journal of the National Cancer Institute (1 paper)Seminars in Oncology (1 paper)
Partner nations: Germany United Kingdom United States

In The Last Decade

H. Döhner

27 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias 1995 · 576 citations

Peers

Countries citing papers authored by H. Döhner

Since Specialization

Citations

This map shows the geographic impact of H. Döhner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Döhner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Döhner more than expected).

Fields of papers citing papers by H. Döhner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Döhner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Döhner. The network helps show where H. Döhner may publish in the future.

Co-authors

The 25 scholars most cited alongside H. Döhner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Döhner Line = papers co-authored together H. Döhner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood ·H. Döhner, Konstanze Fischer, Martin Bentz, Klavs Würgler Hansen, Axel Benner, G Cabot, Daniela Diehl, Richard F. Schlenk, Johannes Coy, Stephan Stilgenbauer, Martin Volkmann, Peter R. Galle, Albert J. Poustka, W. Hunstein, Peter Lichter Hit paper breakdown →	1995	576
2	Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival Haematologica ·Stephan Stilgenbauer, Sandrine Sander, Lars Bullinger, Axel Benner, Elke Leupolt, Dirk Winkler, Alexander Kröber, Dirk Kienle, Peter Lichter, H. Döhner	2007	153
3	Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization Blood ·Martin Bentz, G Cabot, M Moos, MR Speicher, Arnold Ganser, Peter Lichter, H. Döhner	1994	116
4	Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. PubMed ·Martin Dreyling, Lars Bullinger, German Ott, Stephan Stilgenbauer, H. K. Müller-Hermelink, Martin Bentz, W. Hiddemann, H. Döhner	1997	111
5	Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia Leukemia ·Guido Marcucci, MA Caligiuri, H. Döhner, Kellie J. Archer, R. Schlenk, Konstanze Döhner, E A Maghraby, CD Bloomfield	2001	95
6	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials Haematologica ·Valentin Goede, Paula Cramer, R. Busch, Michèle Bergmann, Martina Stauch, Georg Hopfinger, Stephan Stilgenbauer, H. Döhner, Anneke M. Westermann, Clemens‐Martin Wendtner, Barbara Eichhorst, Michael Hallek, (unknown)	2014	72
7	A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). PubMed ·Roel Willemze, Stefan Suciu, E Archimbaud, Petra Muus, Pierre Stryckmans, E A Louwagie, Zwi Berneman, M T'Jean, P. Wijermans, H. Döhner, U. Jehn, Boris Labar, Branimir Jakšić, M Dardenne, R Zittoun	1997	72
8	Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation Leukemia ·Sebastian Böttcher, Matthias Ritgen, Christiane Pott, Monika Brüggemann, Thorsten Raff, Stephan Stilgenbauer, H. Döhner, Peter Dreger, Michael Kneba	2004	67
9	Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia Blood ·Konstanze Fischer, Catharina Scholl, J Salat, Stefan Fröhling, Richard F. Schlenk, Martin Bentz, Stephan Stilgenbauer, Peter Lichter, H. Döhner	1996	64
10	Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids Leukemia ·Martina Seiffert, Stephan Stilgenbauer, H. Döhner, Peter Lichter	2007	57
11	Risk Stratification in Chronic Lymphocytic Leukemia Seminars in Oncology ·T. Seiler, H. Döhner, Stephan Stilgenbauer	2006	56
12	Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia International Journal of Oncology ·Krzysztof Giannopoulos, L Li, Agnieszka Bojarska−Junak, Jacek Roliński, Anna Dmoszyńska, Iwona Hus, Jochen Greiner, C Renner, H. Döhner, Michael Schmitt	2006	54
13	Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group JNCI Journal of the National Cancer Institute ·H. Döhner, Anthony D. Ho, J. Thaler, Pierre Stryckmans, Pieter Sonneveld, Theodore Witte, Klaus Lechner, F. Lauria, S. Bödewadt-Radzun, Stefan Suciu, G. Solbu, Barbara Witt, W. Hunstein, R Zittoun	1993	51
14	Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH) Leukemia ·Swen Weßendorf, Thomas F.E. Barth, Andreas Viardot, Anna Mueller, Hans A. Kestler, Holger Kohlhammer, Peter Lichter, Martin Bentz, H. Döhner, Peter Möller, Carsten Schwäenen	2007	50
15	The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML Leukemia ·Su Ming Sun, Veronika Ročková, Lars Bullinger, M K Dijkstra, H. Döhner, Bob Löwenberg, Mojca Jongen‐Lavrencic	2012	48
16	Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia Leukemia ·Krzysztof Giannopoulos, Anna Dmoszyńska, Małgorzata Kowal, Jacek Roliński, Emma Gostick, David A. Price, Jochen Greiner, Markus Rojewski, Stephan Stilgenbauer, H. Döhner, Michael Schmitt	2010	41
17	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup Haematologica ·Markus Schaich, R. Schlenk, Haifa Kathrin Al‐Ali, H. Döhner, Arnold Ganser, G. Heil, Thomas Illmer, R. Krahl, J. Krauter, Christina Sauerland, Thomas Büchner, Gerhard Ehninger	2007	35
18	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia Haematologica ·Dirk Kienle, Axel Benner, Carolin Läufle, Dirk Winkler, C. Schneider, Andreas Bühler, Thorsten Zenz, Annett Habermann, Ulrich Jäger, Peter Lichter, Riccardo Dalla‐Favera, H. Döhner, S. Stilgenbauer	2009	24
19	Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG Leukemia ·Katarzyna Nowek, Su Ming Sun, Lars Bullinger, Eric M. Bindels, Carla Exalto, M K Dijkstra, Kirsten van Lom, H. Döhner, Stefan J. Erkeland, Bob Löwenberg, Mojca Jongen‐Lavrencic	2015	22
20	Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG) mediaTUM (Technical University of Munich) ·S. Stilgenbauer, Alexander Kröber, Dirk Winkler, Dirk Kienle, Robert Busch, Michael Hallek, M. Hensel, Eva Lengfelder, Lorenz Trümper, Peter Dreger, Ulrich Jäger, H. Döhner	2005	18

About H. Döhner

H. Döhner is a scholar working on Genetics, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health, Immunology and Hematology, having authored 27 papers that have together received 1.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (14 papers), Acute Lymphoblastic Leukemia research (8 papers), Acute Myeloid Leukemia Research (6 papers), Immunodeficiency and Autoimmune Disorders (5 papers), Viral-associated cancers and disorders (4 papers), Genomic variations and chromosomal abnormalities (4 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Genetics (1.1k citations), Pathology and Forensic Medicine (850 citations), Hematology (465 citations), Immunology (507 citations) and Oncology (441 citations). H. Döhner has collaborated with scholars based in Germany, United Kingdom and United States. Frequent co-authors include Stephan Stilgenbauer, Peter Lichter, Martin Bentz, Axel Benner, Konstanze Fischer, Richard F. Schlenk, W. Hunstein, Johannes Coy, Albert J. Poustka and Peter R. Galle. Their work appears in journals such as Leukemia, Haematologica, Blood, JNCI Journal of the National Cancer Institute and Seminars in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact